Does Blue Cross Blue Shield of Minnesota Cover Lantus?

What Is Lantus and Why Does Coverage Vary?

Lantus is a long-acting basal insulin analog manufactured by Sanofi. The active molecule, insulin glargine, lowers blood glucose by stimulating peripheral glucose uptake and suppressing hepatic glucose output, mimicking the body's baseline insulin secretion over roughly 24 hours. The FDA first approved Lantus in April 2000, and it remains one of the most widely prescribed basal insulins in the United States. [1]

Coverage decisions for any brand-name insulin are driven by a plan's Pharmacy Benefit Manager (PBM), formulary design, and negotiated rebate agreements. BCBS MN administers several distinct plan lines, including commercial employer-sponsored plans, individual marketplace plans, Medicare Advantage (through Blue Cross Medicare), and Medicaid-related products (through Blue Plus). Each of those plan lines maintains its own formulary, and Lantus may sit on a different tier, or carry different prior-authorization requirements, depending on which product a patient holds.

How Formulary Tiers Affect Your Lantus Cost

Most BCBS MN commercial formularies organize drugs across four to six tiers:

• Tier 1: Generic drugs, lowest cost-share
• Tier 2: Preferred brand-name drugs
• Tier 3: Non-preferred brand-name drugs, moderate cost-share
• Tier 4: Specialty or high-cost brands, highest cost-share

Lantus most commonly lands on Tier 3 in BCBS MN commercial plans, though some plan designs place it on Tier 4. A Tier 3 placement typically means a copay of $50, $100 per fill or 30 to 40% coinsurance after the deductible, depending on the specific plan design. Patients enrolled in high-deductible health plans (HDHPs) may pay the full negotiated price until the deductible is met.

Biosimilars and Their Preferred Status

The FDA approved Semglee (insulin glargine-yfgn, Biocon/Mylan) as the first interchangeable biosimilar to Lantus in July 2021. [2] "Interchangeable" status means a pharmacist may legally substitute Semglee for a Lantus prescription without a new physician order in all 50 states. Rezvoglar (insulin glargine-aglr, Eli Lilly) received interchangeable designation in December 2022. [3]

Because biosimilars carry lower list prices and generate larger rebates for PBMs, BCBS MN (and most large commercial insurers) incentivizes their use by placing them on Tier 2 or a preferred Tier 3 position. Basaglar (insulin glargine-aglr, Eli Lilly), which launched in 2016 as a "follow-on" insulin rather than a formal biosimilar, is similarly preferred on many BCBS MN formularies. If your provider writes specifically for Lantus and BCBS MN's formulary prefers Basaglar or Semglee, the plan may deny the claim until step therapy or prior authorization criteria are satisfied.

Prior Authorization Requirements for Lantus Under BCBS MN

Prior authorization (PA) is a formal review process requiring your prescribing provider to submit clinical documentation before BCBS MN will approve coverage. PA for Lantus is common across BCBS MN plan lines and is not unique to this insurer. The American Diabetes Association (ADA) 2024 Standards of Care note that "prior authorization and step therapy requirements for insulin add administrative burden and may delay access for patients with diabetes." [4]

What Clinical Criteria Are Typically Required?

While exact criteria differ by plan year and formulary version, BCBS MN PA requests for Lantus commonly require documentation of:

1. A confirmed diagnosis of Type 1 or Type 2 diabetes mellitus (ICD-10: E10.x or E11.x)
2. Evidence that a preferred formulary basal insulin (such as Basaglar or Semglee) was tried and caused an adverse effect, was clinically contraindicated, or produced inadequate glycemic control
3. Current HbA1c value and most recent fasting glucose logs
4. Prescriber attestation that Lantus is medically necessary for this specific patient

The step-therapy requirement, which mandates a trial of the preferred agent first, is the most common reason PA requests for Lantus are initially denied. Minnesota enacted step-therapy reform legislation (Minn. Stat. § 62Q.184) that requires insurers to grant a step-therapy override when a clinician documents that the preferred drug is contraindicated or has previously failed. Providers should cite this statute explicitly in override requests.

How to Submit a Prior Authorization Request

Your prescribing provider (or their clinical staff) initiates the PA through BCBS MN's provider portal or by faxing a completed PA request form. The process generally follows these steps:

1. Provider submits PA with supporting clinical notes, HbA1c values, and any prior insulin trial documentation.
2. BCBS MN's pharmacy team reviews the request, typically within 3 business days for standard requests or 24 to 72 hours for urgent requests.
3. BCBS MN issues an approval, denial, or request for additional information.
4. If denied, the provider and patient each have the right to request a formal appeal.

Under Minnesota law (Minn. Stat. § 62Q.73), plans must resolve standard appeals within 30 days and expedited appeals within 72 hours when a delay would seriously jeopardize health.

Appealing a Lantus Denial

A denial letter from BCBS MN must state the specific clinical reason for denial and list the exact criteria the request did not meet. Your provider should respond point-by-point to those criteria with additional documentation. If the internal appeal is also denied, Minnesota residents may request an external independent review through the Minnesota Department of Commerce. External review requests must be filed within 60 days of receiving the final internal denial.

Lantus Coverage on BCBS MN Medicare Advantage Plans

Patients enrolled in Blue Cross Medicare Advantage plans in Minnesota receive prescription drug coverage through Medicare Part D rules. The Inflation Reduction Act of 2022 capped out-of-pocket costs for all covered insulins at $35 per month for Medicare Part D beneficiaries, a provision that took effect January 1, 2023. [5] This cap applies to Lantus if it appears on the plan's formulary, regardless of formulary tier.

Medicare Advantage formularies are governed by the Centers for Medicare and Medicaid Services (CMS) and must be submitted for annual approval. CMS requires that each Medicare Part D formulary include at least two drugs in each therapeutic category. Lantus competes in the "long-acting insulins" category alongside Basaglar, Semglee, Toujeo (insulin glargine 300 units/mL), Tresiba (insulin degludec), and Levemir (insulin detemir). [6]

Medicare Part D Exception Requests for Lantus

If Lantus does not appear on your specific Blue Cross Medicare Advantage plan's formulary, you may request a formulary exception. Exceptions are granted when your prescriber documents that all covered alternatives are contraindicated or clinically inappropriate. CMS requires plans to resolve standard exception requests within 72 hours. An expedited request must be resolved within 24 hours.

Lantus Coverage Under Blue Plus (Minnesota Medicaid)

Blue Plus is the BCBS-affiliated managed care organization that serves Minnesota Health Care Programs (MHCP) enrollees, including Medical Assistance (Medicaid) and MinnesotaCare members. Minnesota's Medicaid drug formulary is administered under the Minnesota Department of Human Services (DHS) Preferred Drug List (PDL).

For Medicaid-enrolled patients, insulin coverage rules differ materially from commercial plans. Minnesota Medicaid covers insulin glargine products, but preferred status follows state PDL negotiations rather than commercial PBM contracts. Patients should verify their specific Blue Plus plan formulary directly with BCBS MN member services (the number appears on the back of the insurance card) or through the MNsure formulary lookup tool.

Cost Without Coverage: Lantus Prices and Savings Programs

If prior authorization is denied and appeals are exhausted, or if a patient is uninsured, Lantus carries a Wholesale Acquisition Cost (WAC) of approximately $292, $325 per 10 mL vial (100 units/mL) as of 2024. A 10 mL vial provides roughly 1,000 units of insulin, which for a patient using 30 units per day lasts approximately 33 days.

Sanofi reduced the list price of Lantus by 78% in January 2024 as part of a broader industry pricing response to legislative pressure. The new list price is approximately $65 per vial. [7] This reduction is significant, but the price a patient pays at the pharmacy counter still depends on their plan's negotiated rate and cost-share structure.

Manufacturer Patient Assistance Programs

Sanofi's Insulins Valyou Savings Program caps Lantus costs at $99 for a 90-day supply for eligible commercially insured patients who meet income criteria. Patients without insurance may qualify for Sanofi's Patient Assistance Program (Sanofi Patient Connection), which can provide Lantus at no cost. Eligibility is income-based and must be renewed periodically.

GoodRx and Pharmacy Discount Cards

GoodRx and similar pharmacy discount programs can reduce the cash price of Lantus at many Minnesota pharmacies. GoodRx prices for a 10 mL vial of Lantus in the Minneapolis-Saint Paul metro area ranged from approximately $68, $110 as of early 2025, depending on the pharmacy and coupon used. These discount cards cannot be used simultaneously with insurance benefits on the same prescription.

Biosimilar Price Advantage

Semglee's list price was set at approximately $147 per vial at launch, roughly a 65% discount to Lantus's pre-2024 list price. With Sanofi's January 2024 price reduction, the cost differential has narrowed, but BCBS MN may still prefer Semglee due to ongoing rebate arrangements. A 2022 analysis in JAMA Internal Medicine found that insulin list price reductions do not always translate to lower patient out-of-pocket costs when PBM rebate structures are involved. [8]

Clinical Equivalence: Is Lantus Worth Pursuing Over Biosimilars?

The FDA's designation of Semglee and Rezvoglar as interchangeable biosimilars is grounded in rigorous pharmacokinetic, pharmacodynamic, and immunogenicity studies demonstrating no clinically meaningful difference from Lantus. [2, 3] A 2018 randomized controlled trial published in Diabetes Care (N=535) found that insulin glargine biosimilar (MYL-1501D, later approved as Semglee) produced HbA1c reductions and hypoglycemia rates statistically equivalent to Lantus over 52 weeks in patients with Type 1 diabetes. [9]

The clinical case for insisting on brand-name Lantus over an FDA-designated interchangeable biosimilar is narrow. Situations where a provider might legitimately pursue a PA for Lantus despite formulary preference for a biosimilar include:

• A documented injection-site reaction or hypersensitivity to a specific biosimilar excipient not present in Lantus
• A patient stabilized on Lantus for years who demonstrates significant glycemic variability on any previous switch attempt (with glucose logs as documentation)
• Pen device compatibility issues where the patient's existing supplies or physical limitations make the Lantus SoloStar pen specifically necessary

The ADA 2024 Standards of Care state: "Insulin-treated patients may be switched from one insulin preparation to another equivalent preparation (e.g., from Lantus to Basaglar or Semglee) with appropriate monitoring for changes in glycemic response." [4] This guidance supports the biosimilar-first approach that most formularies, including BCBS MN's, have adopted.

Toujeo as an Alternative Long-Acting Insulin

Toujeo (insulin glargine 300 units/mL) is another Sanofi product containing the same active molecule as Lantus but at three times the concentration. Because Toujeo is a distinct product (not a biosimilar), it occupies a separate formulary position. A 2015 randomized trial (EDITION I, N=807) found Toujeo produced similar HbA1c reductions to Lantus U-100 in Type 2 diabetes patients on basal-bolus regimens, with a statistically significant reduction in confirmed nocturnal hypoglycemia (P<0.05). [10]

On some BCBS MN plan designs, Toujeo holds a preferred Tier 2 position. Providers who believe a patient needs a higher-concentration glargine formulation (such as patients requiring large basal doses above 80 units/day) may find Toujeo easier to access than Lantus under the current formulary structure.

Step-by-Step Action Plan for BCBS MN Members Who Need Lantus

1. Verify your specific formulary. Log into your BCBS MN member portal at bluecrossmn.com and use the drug cost estimator to confirm Lantus's current tier and PA requirements for your specific plan. Formularies can change annually and mid-year with advance notice.

2. Ask your provider to check preferred alternatives first. If Basaglar, Semglee, or Toujeo are clinically appropriate, using a preferred agent avoids the PA process entirely and reduces your cost-share.

3. If Lantus is medically necessary, initiate PA immediately. Do not wait until you are at the pharmacy counter. Have your provider submit the PA before the prescription is sent to the pharmacy.

4. Document everything for step-therapy override. If you previously tried a preferred agent and had problems, compile glucose logs, HbA1c values, and any documentation of adverse effects. Specificity strengthens the override request.

5. File a formal appeal if denied. Use BCBS MN's standard appeal form. Your provider's office should send a cover letter citing the specific clinical reason Lantus is necessary, referencing Minn. Stat. § 62Q.184 if step therapy was improperly applied.

6. Request an external review if the internal appeal fails. Contact the Minnesota Department of Commerce (mn.gov/commerce) to initiate an independent external review. This process is free to the patient.

7. Explore cost-assistance programs in parallel. Apply for Sanofi's Insulins Valyou Savings Program or Patient Assistance Program while the PA or appeal is pending, so you are not without insulin during the review period. The FDA's guidance on insulin access programs is publicly available at FDA.gov. [11]

What Minnesota Law Says About Insulin Cost-Sharing

Minnesota enacted the Alec Smith Emergency Insulin Act (Minn. Stat. § 151.74) in 2020, which requires Minnesota health insurers and pharmacy benefit managers to provide emergency insulin supplies to patients who cannot afford their cost-share. Under this law, a Minnesota resident who is insured and cannot pay for insulin may receive a 30-day emergency supply from a licensed pharmacy at no charge, up to a $35 cap per insulin product, while working on a longer-term coverage solution.

This law does not waive the PA requirement or change your plan's formulary, but it prevents a gap in insulin access during administrative delays. The CDC estimates that approximately 8.4 million Americans use insulin, and cost-related underuse of insulin is associated with increased rates of diabetic ketoacidosis and hospitalization. [12]